Kazia Therapeutics Limited
KZIA · NASDAQ
6/30/2025 | 6/30/2024 | 6/30/2023 | 6/30/2022 | |
|---|---|---|---|---|
| Revenue | $42 | $2,308 | $1 | $10 |
| % Growth | -98.2% | 415,755.9% | -94.5% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $42 | $2,308 | $1 | $10 |
| % Margin | 100% | 100% | 100% | 100% |
| R&D Expenses | $7,326 | $17,380 | $15,564 | $20,169 |
| G&A Expenses | $8,720 | $13,563 | $8,583 | $5,113 |
| SG&A Expenses | $8,720 | $13,563 | $8,583 | $5,240 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $127 |
| Other Operating Expenses | -$1,787 | -$173 | -$23 | $0 |
| Operating Expenses | $14,259 | $30,770 | $24,125 | $25,409 |
| Operating Income | -$14,217 | -$28,462 | -$24,124 | -$25,399 |
| % Margin | -33,850% | -1,233.2% | -4,346,661.1% | -253,990% |
| Other Income/Exp. Net | -$8,231 | $1,413 | $3,410 | $17 |
| Pre-Tax Income | -$22,448 | -$27,049 | -$20,736 | -$25,382 |
| Tax Expense | -$1,746 | -$271 | -$271 | -$368 |
| Net Income | -$20,702 | -$26,778 | -$20,465 | -$25,014 |
| % Margin | -49,290.5% | -1,160.2% | -3,687,419.8% | -250,140% |
| EPS | -18.9 | -55 | -55 | -95 |
| % Growth | 65.6% | 0% | 42.1% | – |
| EPS Diluted | -18.9 | -55 | -55 | -95 |
| Weighted Avg Shares Out | 1,095 | 480 | 369 | 265 |
| Weighted Avg Shares Out Dil | 1,095 | 480 | 369 | 265 |
| Supplemental Information | – | – | – | – |
| Interest Income | $72 | $12 | $23 | $2 |
| Interest Expense | $0 | $0 | $0 | $2 |
| Depreciation & Amortization | $934 | $1,869 | $1,869 | $1,869 |
| EBITDA | -$13,283 | -$26,593 | -$22,277 | -$23,515 |
| % Margin | -31,626.2% | -1,152.2% | -4,013,885.9% | -235,150% |